T
Tilman Sauerbruch
Researcher at University of Bonn
Publications - 697
Citations - 27943
Tilman Sauerbruch is an academic researcher from University of Bonn. The author has contributed to research in topics: Cirrhosis & Portal hypertension. The author has an hindex of 88, co-authored 685 publications receiving 26429 citations. Previous affiliations of Tilman Sauerbruch include Goethe University Frankfurt & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
Naztfa Qurishi,Christina Kreuzberg,Guido Lüchters,W. Effenberger,Bernd Kupfer,Tilman Sauerbruch,Jürgen K. Rockstroh,Ulrich Spengler +7 more
TL;DR: In addition to improved overall survival, antiretroviral therapy significantly reduced long-term liver-related mortality in patients and seems to outweigh by far the associated risks of severe hepatotoxicity.
Journal ArticleDOI
Fragmentation of gallstones by extracorporeal shock waves
Tilman Sauerbruch,Michael Delius,Gustav Paumgartner,Josef Holl,Othmar Dr. Wess,Werner Weber,Wolfgang Dr Hepp,Walter Brendel +7 more
TL;DR: It is concluded that gallstone disease may be treated successfully and without serious adverse effects by extracorporeally generated shock waves in selected patients.
Journal ArticleDOI
Shock-wave lithotripsy of gallbladder stones. The first 175 patients.
M. Sackmann,Michael Delius,Tilman Sauerbruch,J. Holl,Werner Weber,E Ippisch,U Hagelauer,Othmar Dr. Wess,Wolfgang Dr Hepp,Walter Brendel +9 more
TL;DR: Extracorporeal shock-wave lithotripsy combined with medical therapy for stone dissolution is a safe and effective treatment in selected patients with radiolucent gallbladder calculi.
Journal ArticleDOI
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial
Rafael Bañares,Rafael Bañares,Frederik Nevens,Fin Stolze Larsen,Rajiv Jalan,Agustín Albillos,Matthias M. Dollinger,Faouzi Saliba,Faouzi Saliba,Tilman Sauerbruch,Sebastian Klammt,Johann Ockenga,Albert Parés,Julia Wendon,Tanja Brünnler,Ludwig Kramer,Philippe Mathurin,Manuel de la Mata,Antonio Gasbarrini,Beat Müllhaupt,Alexander Wilmer,Wim Laleman,Martin Eefsen,Sambit Sen,Alexander Zipprich,Teresa Tenorio,Marco Pavesi,Hartmut Schmidt,Steffen Mitzner,Roger Williams,Vicente Arroyo +30 more
TL;DR: At scheduled doses, a beneficial effect on survival of MARS therapy in patients with ACLF could not be demonstrated, however, MARS has an acceptable safety profile, has significant dialysis effect, and nonsignificantly improves severe HE.
Journal ArticleDOI
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo‐controlled trial
Ulrich Beuers,Ulrich Spengler,Wolfgang Kruis,ülker Aydemir,Baldur Wiebecke,Walter Heldwein,M. Weinzierl,Gerd R. Pape,Tilman Sauerbruch,Gustav Paumgartner +9 more
TL;DR: It is concluded that ursodeoxycholic acid is beneficial in reducing disease activity in patients with primary sclerosing cholangitis and histopathological features improved significantly, as evaluated by multiparametric score.